Russell  Jones, PhD

Russell Jones, PhD

Van Andel Institute

Chair and Professor, Department of Metabolism and Nutritional Programming

Expertise: Cancer ImmunologyCancer Immunologycancer metabolismcancer metabolismCell MetabolismCell Metabolism

Dr. Russell Jones is a leading expert in the study of cancer metabolism and immunology. As professor and program lead of the Metabolic and Nutritional Programming group at Van Andel Research Institute, his work seeks to uncover how cancer cells fuel themselves through metabolic interactions, with the ultimate goal of developing new cancer therapeutics.  

He earned his B.Sc. with honors in Biochemistry and his Ph.D. in Medical Biophysics from the University of Toronto, where he studied in the lab of Dr. Pamela S. Ohashi. After completing a postdoctoral fellowship in the lab of Dr. Craig B. Thompson at University of Pennsylvania in 2008, he accepted a position as an assistant professor in the Department of Physiology and Goodman Cancer Research Centre at McGill University. He was subsequently promoted to associate professor in 2014 and, in 2017, also took on the role of director of the Metabolomics Core Facility at Goodman Cancer Research Centre. He joined Van Andel Research Institute’s Center for Cancer and Cell Biology in 2018 as program lead and a founding member of its Metabolic and Nutritional Programming group. Dr. Jones has earned numerous accolades throughout his career, including a New Investigator Award from the Canadian Institutes of Health Research, the Bernard and Francine Dorval Prize from the Canadian Cancer Society, and several teaching awards at McGill University. He was named a William Dawson Scholar in 2014 and elected to the College of New Scholars, Artists and Scientists of the Royal Society of Canada in 2015. He also serves as a reviewer for a number of journals, including Cell Metabolism, Immunity, Nature, Nature Immunology and Science.

Title

Cited By

Year

Alternative cellular ‘fuels’ boost immunity

A metabolic by-product that is more prevalent during fasting may supercharge immune cells as they fight infection and disease, reports an early stage study by Van Andel Institute scientists and collaborators.
28-Jul-2023 11:05:11 AM EDT

Targeting uncontrolled inflammation may hold the key to treating therapy-resistant cancers

Van Andel Institute scientists have pinpointed how a specific gene mutation triggers an inflammatory cascade that may drive development of treatment-resistant cancers.
11-May-2023 01:15:51 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister
close
0.08027